Home » Stocks » LNDC

Landec Corporation (LNDC)

Stock Price: $10.41 USD 0.20 (1.96%)
Updated November 24, 4:00 PM EST - Market closed
After-hours: $10.27 -0.14 (-1.35%) Nov 24, 4:37 PM

Stock Price Chart

Key Info

Market Cap 304.41M
Revenue (ttm) 587.30M
Net Income (ttm) -44.41M
Shares Out 29.24M
EPS (ttm) -1.53
PE Ratio n/a
Forward PE 227.27
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $10.41
Previous Close $10.21
Change ($) 0.20
Change (%) 1.96%
Day's Open 10.24
Day's Range 10.18 - 10.49
Day's Volume 84,966
52-Week Range 7.48 - 12.09

More Stats

Market Cap 304.41M
Enterprise Value 504.78M
Earnings Date (est) Jan 6, 2021
Ex-Dividend Date n/a
Shares Outstanding 29.24M
Float 28.48M
EPS (basic) -1.52
EPS (diluted) -1.53
FCF / Share -0.30
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.18M
Short Ratio 7.35
Short % of Float 4.14%
Beta 1.07
PE Ratio n/a
Forward PE 227.27
P/FCF Ratio n/a
PS Ratio 0.52
PB Ratio 1.35
Revenue 587.30M
Operating Income -46.83M
Net Income -44.41M
Free Cash Flow -8.64M
Net Cash -200.38M
Net Cash / Share -6.85
Gross Margin 12.26%
Operating Margin -7.97%
Profit Margin -7.60%
FCF Margin -1.47%
ROA -0.94%
ROE -18.27%
ROIC -10.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 5
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$14.00*
(34.49% upside)
Low
12.0
Current: $10.41
High
15.0
Target: 14.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue590558524470477539477442318277
Revenue Growth5.88%6.36%11.59%-1.5%-11.56%13.1%7.95%39.1%14.75%-
Gross Profit74.9981.0078.3479.2166.7865.4162.5662.7652.1446.70
Operating Income-38.545.4813.5914.67-20.6318.4620.1924.8714.588.03
Net Income-38.190.4124.8310.59-11.6413.5419.1522.5912.703.92
Shares Outstanding29.1628.3627.5427.2827.0426.8826.6325.8325.8526.40
Earnings Per Share-1.310.010.890.38-0.430.500.710.850.490.15
EPS Growth--98.88%134.21%---29.58%-16.47%73.47%226.67%-
Operating Cash Flow-17.0416.0219.7829.8420.7626.6221.0521.2322.1814.47
Capital Expenditures-24.25-44.47-33.49-22.92-39.57-16.44-14.89-8.88-5.37-6.68
Free Cash Flow-41.29-28.45-13.716.92-18.8110.186.1612.3516.817.79
Cash & Equivalents0.361.082.906.009.8914.1314.2415.2622.1836.26
Total Debt22115372.9453.9761.1542.5234.3744.3158.9819.83
Net Cash / Debt-221-152-70.04-47.97-51.26-28.39-20.13-29.04-36.8116.43
Assets541519405359343346314291278206
Liabilities31024915213013012610911112668.59
Book Value231270253227211218203179150136
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Landec Corporation
Country United States
Employees 796
CEO Albert D. Bolles

Stock Information

Ticker Symbol LNDC
Stock Exchange NASDAQ
Sector Consumer Defensive
Industry Packaged Foods
Unique Identifier NASDAQ: LNDC
IPO Date February 15, 1996

Description

Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets. It operates through Curation Foods and Lifecore segments. The Curation Foods segment engages in processing, marketing, and selling of vegetable-based salads, and fresh-cut and whole vegetable products primarily under the Eat Smart brand, O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products, as well as various private labels. It serves retail grocery chains, club stores, and food service operators. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology transfer, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. It sells its products directly to partners in the medical device and pharmaceutical markets. The company was founded in 1986 and is headquartered in Santa Clara, California.